DOI QR코드

DOI QR Code

Synergistic Effects of Tamoxifen and Tranilast on VEGF and MMP-9 Regulation in Cultured Human Breast Cancer Cells

  • Darakhshan, Sara (Department of Biology, Faculty of Science, Razi University) ;
  • Bidmeshkipour, Ali (Department of Biology, Faculty of Science, Razi University) ;
  • Khazaei, Mozafar (Fertility and Infertility Research Center, Kermanshah University of Medical Sciences) ;
  • Rabzia, Arezou (Fertility and Infertility Research Center, Kermanshah University of Medical Sciences) ;
  • Ghanbari, Ali (Fertility and Infertility Research Center, Kermanshah University of Medical Sciences)
  • Published : 2013.11.30

Abstract

Background: Vascular endothelial growth factor and matrix metalloproteinases are two important factors for angiogenesis associated with breast cancer growth and progression. The present study was aimed to examine the effects of tamoxifen and tranilast drugs singly or in combination on proliferation of breast cancer cells and also to evaluate VEGF and MMP-9 expression and VEGF secretion levels. Materials and Methods: Human breast cancer cell lines, MCF-7 and MDA-MB-231, were treated with tamoxifen and/or tranilast alone or in combination and percentage cell survival and proliferative activity were evaluated using LDH leakage and MTT assays. mRNA expression and protein levels were examined by real-time RT-PCR and ELISA assay, respectively. Results: LDH and MTT assays showed that the combined treatment of tamoxifen and tranilast resulted in a significant decrease in cell viability and cell proliferation compared with tamoxifen or tranilast treatment alone, with significant decrease in VEGF mRNA and protein levels. We also found that tamoxifen as a single agent rarely increased MMP-9 expression. A decrease in MMP-9 expression was seen after treatment with tranilast alone and in the combined treatment MMP-9 mRNA level was decreased. Conclusions: This combination treatment can able to inhibit growth, proliferation and angiogenesis of breast cancer cells.

Keywords

Breast cancer;tamoxifen;tranilast;angiogenesis;matrix metalloproteinase

References

  1. Lymperatou D, Efstathia Giannopoulou E, Koutras AK, Kalofonos HP (2013). The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently. Bio Med Res Int, 2013, 147514.
  2. Mitsuno M Kitajima Y, Ohtaka K, et al (2010). Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. Int J Oncol, 36, 341-9.
  3. Nilsson U, Garvin S, Dabrosin C (2007). MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat, 102, 253-61. https://doi.org/10.1007/s10549-006-9335-4
  4. Nilsson UW, Dabrosin C (2006). Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res, 66, 4789-94. https://doi.org/10.1158/0008-5472.CAN-05-4012
  5. Noguchi N, Kawashiri S, Tanaka A, et al (2003). Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncol, 39, 240-7. https://doi.org/10.1016/S1368-8375(02)00092-1
  6. Perrot-Applanat M, Di Benedetto M (2012). Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adh Migr, 6, 547-53. https://doi.org/10.4161/cam.23332
  7. Petrangeli E, Lubrano C, Ortolani F, et al (1994). Estrogen receptors: new perspectives in breast cancer management. J Steroid Biochem Mol Biol, 49, 327-31. https://doi.org/10.1016/0960-0760(94)90275-5
  8. Pilips N, McFadden K (2004). Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cells. Cancer Lett, 206, 63-8. https://doi.org/10.1016/j.canlet.2003.10.019
  9. Rajput S, Kumar BN, Sarkar S, et al (2013). Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated AKT regulation in breast cancer. Plos One, 8, 61342. https://doi.org/10.1371/journal.pone.0061342
  10. Schneider BP, Sledge Jr GW (2007). Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol, 4, 181-9.
  11. Subramaniam V, Ace O, Prud’homme GJ, et al (2011). Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Exp Mol Pathol, 90, 116-22. https://doi.org/10.1016/j.yexmp.2010.10.012
  12. Subramaniam V, Chakrabarti R, Prud'homme GJ, Jothy S (2010). Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs, 21, 351-61. https://doi.org/10.1097/CAD.0b013e328334992c
  13. Van den Brule FA, Engel J, Stetler-Stevenson WG, et al (1992). Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer, 52, 653-7. https://doi.org/10.1002/ijc.2910520426
  14. Versteeg HH, Schaffner F, Kerver M, et al (2008). Inhibition of tissue factor signaling suppresses tumor growth. Blood, 111, 190-9. https://doi.org/10.1182/blood-2007-07-101048
  15. Weidner N, Folkman J, Pozza F, et al (1992). Tumor angiogenesis: a new significant andindependent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst, 84, 1875-87. https://doi.org/10.1093/jnci/84.24.1875
  16. Yamamoto M, Yamauchi T, Okano K et al (2009). Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku J Exp Med, 217, 193-201. https://doi.org/10.1620/tjem.217.193
  17. Ahluwalia AS, Tarnawski A (2012). Critical role of hypoxia sensor-HIF-1 in VEGF gene activation. implications for angiogenesis and tissue injury healing. Curr Med Chem, 19, 90-7. https://doi.org/10.2174/092986712803413944
  18. Applanat MP, Buteau-Lozano H, Herve MA, Corpet A (2008). Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol, 617, 437-44. https://doi.org/10.1007/978-0-387-69080-3_42
  19. Azuma H, Banno K, Yoshimura T (1976). Pharmacological properties of N-(3', 4'- dimethoxycinnamoyl) anthranilic acid (N-5'), a new anti-atopic agent. Br J Pharmacol, 58, 483-8. https://doi.org/10.1111/j.1476-5381.1976.tb08614.x
  20. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol, 4, 536-50.
  21. Bergers G, Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3, 401-10. https://doi.org/10.1038/nrc1093
  22. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ (2009). Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs, 20, 334-45. https://doi.org/10.1097/CAD.0b013e328327994e
  23. Cole MP, Jones CT, Todd ID (1971). A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer, 25, 270-5. https://doi.org/10.1038/bjc.1971.33
  24. Abbas Abidi SM, Howard EW, Dmytryk JJ, Pento JT (1997). Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metastasis, 15, 432-9. https://doi.org/10.1023/A:1018458406797
  25. Dabrosin C, Margetts PJ, Gauldie J (2003). Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J Cancer, 107, 535-40. https://doi.org/10.1002/ijc.11398
  26. Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76. https://doi.org/10.1038/nm0603-669
  27. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82, 4-6. https://doi.org/10.1093/jnci/82.1.4
  28. Garvin S, Dabrosin C (2003). Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo, Cancer Res, 63, 8742-48.
  29. Garvin S, Nilsson U, Dabrosin C (2005). Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells, Br J Cancer, 93, 1005-10. https://doi.org/10.1038/sj.bjc.6602824
  30. Garvin S, Nilsson UW, Huss FR, Kratz G, Dabrosin C (2006). Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res, 325, 245-51. https://doi.org/10.1007/s00441-006-0159-7
  31. Gialeli C, Theocharis AD, Karamanos NK (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The FEBS Journal, 1, 16-27.
  32. Hsieh GS, Acosta D (1991). Dithranol-induced cytotoxicity in primary cultures of rat epidermal keratinocytes. Toxicol Appl Pharmacol, 107, 16-26. https://doi.org/10.1016/0041-008X(91)90326-A
  33. Izumi K, Mizokami A, Shima T, et al (2010). Preliminary results of tranilast treatment for patients with advanced castration resistant prostate cancer. Anticancer Res, 30, 3077-81.
  34. Jordan VC (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov, 2, 205-13. https://doi.org/10.1038/nrd1031
  35. Kazi AA, Koos RD (2007). Estrogen-induced activation of hypoxia inducible factor 1$\alpha$ (HIF-1$\alpha$), vascular endothelial growth factor (VEGF) expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Endocrinology, 148, 2363-74. https://doi.org/10.1210/en.2006-1394
  36. Khosravi Shahi P, Soria Lovelle A, Perez Manga G (2009). Tumoral angiogenesis and breast cancer. Clin Transl Oncol, 11, 138-42. https://doi.org/10.1007/S12094-009-0329-7
  37. Kousidoua OC, Berdiakib A, Kletsasc D, et al (2008). Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncology, 2, 223-32. https://doi.org/10.1016/j.molonc.2008.06.002
  38. Kumar BNP, Rajput S, Kumar Dey K, et al (2013). Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer, 13, 273. https://doi.org/10.1186/1471-2407-13-273
  39. Linderholm B, Bergqvist J, Hellborg H, et al (2009). Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. Med Oncol, 26, 480-90. https://doi.org/10.1007/s12032-008-9157-9
  40. Littlepage LE, Sternlicht MD, Rougier N, et al (2010). Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res, 70, 2224-34. https://doi.org/10.1158/0008-5472.CAN-09-3515

Cited by

  1. Radixin Knockdown by RNA Interference Suppresses Human Glioblastoma Cell Growth in Vitro and in Vivo vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9805
  2. Cinobufacin Suppresses Cell Proliferation via miR-494 in BGC-823 Gastric Cancer Cells vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1241
  3. Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3113
  4. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6783
  5. Prognostic Factors Influencing Clinical Outcomes of Malignant Glioblastoma Multiforme: Clinical, Immunophenotypic, and Fluorescence in Situ Hybridization Findings for 1p19q in 816 Chinese Cases vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.971
  6. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells vol.234, pp.1, 2018, https://doi.org/10.1002/jcp.27013
  7. The Role of Desmoplasia and Stromal Fibroblasts on Anti-cancer Drug Resistance in a Microengineered Tumor Model vol.11, pp.5, 2018, https://doi.org/10.1007/s12195-018-0544-9